RBC Capital increases Stryker price target to $120 — 5 key facts

RBC Capital increased its price target on Stryker shares from $108 to $120, according to Web Breaking News.

Advertisement

Here are five key facts:

 

1. RBC Capital has an “outperform” rating on Stryker shares.

 

2. Stryker has a market cap of $40.84 billion.

 

2. The P/E ratio is 28.97.

 

4. The company’s 52-week low is $86.68 and 52-week high is $113.85.

 

5. For the first quarter of 2016, Stryker reported net earnings reaching $402 million, up $79.5 million in the first quarter the year prior.

 

More device news:
Stryker’s net earnings up 79.5%; Orthopedics sales reach $1.1B: 9 key notes on Q1 2016
FDA clears Exatech’s Vantage Total Ankle — 5 highlights
Medtech’s ROSA system to be featured at AANS annual meeting — 3 quick notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.